Taiwan Liposome
Clinical-stage biotechnology company developing lipid-engineered medicines. Areas of focus include sustained-release lipid formulations for long-acting injectables, targeted lipid nanoparticle delivery for in vivo gene delivery, liposomal formulations for small molecules and biologics, and a pipeline spanning orthopedics, pain management, metabolic disease, autoimmune disorders, and infectious disease.
Industries
Nr. of Employees
medium (51-250)
Patents
Sustained-release pharmaceutical compositions comprising of a sedative drug and uses thereof
US-12629354-B2
View DetailsLiposomal sustained-release compositions containing a therapeutic drug and use thereof
US-12599557-B2
View DetailsPharmaceutical composition of intra-articular corticosteroid for pain control
US-12514820-B2
View DetailsSustained-release pharmaceutical compositions comprising an antipsychotic drug and uses thereof
US-12285524-B2
View Details
Sustained-release pharmaceutical compositions comprising of a sedative drug and uses thereof
US-12629354-B2
View DetailsLiposomal sustained-release compositions containing a therapeutic drug and use thereof
US-12599557-B2
View DetailsPharmaceutical composition of intra-articular corticosteroid for pain control
US-12514820-B2
View DetailsSustained-release pharmaceutical compositions comprising an antipsychotic drug and uses thereof
US-12285524-B2
View DetailsProducts
TLC518 — once-monthly long-acting GLP-1 injectable formulation
A long-acting injectable formulation of a GLP-1 receptor agonist using a sustained-release lipid delivery system designed to enable monthly dosing with reduced peak exposure and improved tolerability.
tLNP CAR-T — in vivo CAR-T using targeted LNPs
An in vivo CAR‑T program delivering CAR‑encoding nucleic acids to T cells via targeted lipid nanoparticles to enable off‑the‑shelf, redosable CAR‑T therapies without ex vivo manufacturing or chemotherapy preconditioning.
Ampholipad (liposomal amphotericin B for injection)
Liposomal formulation of amphotericin B for treatment of systemic fungal infections, formulated to improve tissue targeting and reduce nephrotoxicity compared with conventional amphotericin B formulations.
TLC599 — dexamethasone extended‑release liposome injection
Extended-release liposomal dexamethasone injection intended for osteoarthritis pain and potential disease‑modifying structural benefits; clinical development through late‑stage trials.
TLC590 — ropivacaine extended‑release injectable suspension
Extended‑release formulation of a local anesthetic for surgical infiltration and nerve block with the goal of long‑lasting postoperative pain control.
TLC501 — gene therapy candidate for articular tissue regeneration
Gene‑delivery candidate intended to support articular tissue regeneration for orthopedic indications using lipid‑based delivery approaches.
TLC518 — once-monthly long-acting GLP-1 injectable formulation
A long-acting injectable formulation of a GLP-1 receptor agonist using a sustained-release lipid delivery system designed to enable monthly dosing with reduced peak exposure and improved tolerability.
tLNP CAR-T — in vivo CAR-T using targeted LNPs
An in vivo CAR‑T program delivering CAR‑encoding nucleic acids to T cells via targeted lipid nanoparticles to enable off‑the‑shelf, redosable CAR‑T therapies without ex vivo manufacturing or chemotherapy preconditioning.
Ampholipad (liposomal amphotericin B for injection)
Liposomal formulation of amphotericin B for treatment of systemic fungal infections, formulated to improve tissue targeting and reduce nephrotoxicity compared with conventional amphotericin B formulations.
TLC599 — dexamethasone extended‑release liposome injection
Extended-release liposomal dexamethasone injection intended for osteoarthritis pain and potential disease‑modifying structural benefits; clinical development through late‑stage trials.
TLC590 — ropivacaine extended‑release injectable suspension
Extended‑release formulation of a local anesthetic for surgical infiltration and nerve block with the goal of long‑lasting postoperative pain control.
TLC501 — gene therapy candidate for articular tissue regeneration
Gene‑delivery candidate intended to support articular tissue regeneration for orthopedic indications using lipid‑based delivery approaches.
Expertise Areas
- Lipid-based drug delivery
- In vivo CAR‑T and immune cell gene delivery
- Sustained‑release long‑acting injectable development
- Liposomal formulation development
Key Technologies
- Targeted lipid nanoparticles
- Liposomal encapsulation technologies
- Sustained‑release lipid assembly methods
- mRNA and nucleic‑acid delivery platforms
News & Updates
Announcement describing expansion into Australia.
Company announced completion of a Phase 2 pharmacokinetic trial for a dexamethasone extended‑release product in Japan, enabling progression toward multinational Phase 3 planning.
Company announced completion of last patient visit in a Phase 3 trial for an extended‑release local anesthetic for postsurgical pain.
Company to provide business and pipeline updates at investor conference.
Company to provide business and pipeline updates at investor conference.
Company to present Phase 3 programs, integrated GMP manufacturing capabilities, and global development strategies ahead of planned listing.
Announcement describing expansion into Australia.
Company announced completion of a Phase 2 pharmacokinetic trial for a dexamethasone extended‑release product in Japan, enabling progression toward multinational Phase 3 planning.
Company announced completion of last patient visit in a Phase 3 trial for an extended‑release local anesthetic for postsurgical pain.
Company to provide business and pipeline updates at investor conference.
Company to provide business and pipeline updates at investor conference.
Company to present Phase 3 programs, integrated GMP manufacturing capabilities, and global development strategies ahead of planned listing.